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The HIV-1 Nef protein is present within the virion and is processed there by the viral protease. Mutational analysis
indicated that residues 54–60 in HIV-1 Nef were required for intravirion cleavage. When viruses were produced using T cell
lines or primary lymphoblasts, these residues were also required for optimal viral infectivity. However, substitution of native
Nef residues with those of a functional Gag cleavage site demonstrated that intravirion cleavage was insufficient for the
virological function of this domain. Furthermore, the importance of certain cleavage site residues to infectivity was
conditional on the producer cell type. In particular, a mutant containing a deletion of residues 54–57 was phenotypically nef
defective when produced using T cells (CEM, A2.01, or primary lymphoblasts) but was minimally impaired when produced
from 293 or HeLa cells. This mutant was cleavage resistant, indicating that proteolytic processing of Nef was dispensable
for infectivity enhancement when virions were assembled in certain non-T cells. Residues 54–61 of the cleavage site,
including 54–57, were also required for Nef-mediated down-regulation of CD4. However, the surface expression of CD4 on
HeLa cells in amounts comparable to that on the surface of primary T lymphoblasts did not create a producer cell
environment in which residues 54–57 acquired greater virological importance. Furthermore, these residues were required for
optimal infectivity even during virion assembly in T cells (A2.01) that expressed a CD4 molecule that is unable to respond to
Nef. These data suggested that in producer T cells, certain cleavage site residues (54–57) contribute to a Nef-mediated
virological effect that is unlikely to be linked causally to CD4 down-regulation. Conversely, in the context of 293 cells as viral
producers, the D54–57 mutant separated genetically down-regulation of CD4 (for which it was defective) from enhancement
of infectivity (for which it was functional). Together, these data indicate that the virological function of the cleavage site
domain is both independent of intravirion proteolytic processing of Nef and independent of CD4 down-regulation. © 1998
Academic Press
INTRODUCTION
The nef gene of primate lentiviruses is an important
virulence factor in animal models of infection (Kestler et
al., 1991). The observation that certain long-term survi-
vors of HIV-1 infection harbor nef-defective viral ge-
nomes further suggests a critical role for nef in human
disease (Deacon et al., 1995). In vitro, nef is required for
efficient viral replication in both cultures of immortalized
T cells and in primary cultures of peripheral blood mono-
nuclear cells (PBMCs) (Chowers et al., 1994; de Ronde et
al., 1992; Miller et al., 1994; Ryan-Graham and Peden,
1995; Spina et al., 1994).
The mechanism by which nef enhances viral replica-
tion and pathogenesis is not understood. Several func-
tions have been ascribed to the nef gene that might
account for these properties. First, Nef down-regulates
CD4 and MHC class I from the cell surface by enhancing
the rate of endocytosis of these receptors from the
plasma membrane (Aiken et al., 1994; Garcia et al., 1994;
Schwartz et al., 1996). Second, Nef influences certain
signal transduction and T cell activation events, possibly
as a result of association with cellular kinases via its
SH3-binding domain (Baur et al., 1994; Collette et al.,
1996; Du et al., 1995; Greenway et al., 1995). Third, ex-
pression of Nef within an infected cell increases the
infectivity of progeny viral particles by an incompletely
characterized mechanism (Chowers et al., 1994; Miller et
al., 1994, 1995; Schwartz et al., 1995).
To enhance infectivity, Nef modifies the virion during
its production. Provision of Nef in trans to genetically
nef-negative virus during its production restores virion
infectivity to wild-type levels and also restores the pro-
ductivity of the progeny virions to wild-type levels for one
subsequent cycle of replication (Miller et al., 1995; Pan-
dori et al., 1996). Furthermore, the finding that nef-nega-
tive virus is impaired in its ability to synthesize viral DNA
in the newly infected cell indicates that the infectivity
phenotype is manifest before viral gene expression in
the target cell (Aiken and Trono, 1995; Chowers et al.,
1995; Schwartz et al., 1995).
Enhancement of infectivity is a phenomenon which is
determined during viral assembly in the producer cell,
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and a variety of producer cell types are capable of
providing an environment permissive for this function of
Nef. Nef-mediated infectivity enhancement does not re-
quire viral production by T cells or even by CD4-positive
cells; cells such as COS or 293 appear to support effi-
ciently the ability of Nef to enhance virion infectivity
(Aiken and Trono, 1995; Miller et al., 1994, 1995). In fact,
no producer cell type has yet been identified that fails to
support this function of Nef, including cells that express
mutant CD4 molecules that cannot respond to Nef or
cells that lack MHC class I (Le Gall et al., 1997; Schwartz
et al., 1995). These data have led to the conclusion that
the effect of Nef on the expression of these cellular
receptors is unrelated causally to the virion modification
that enhances infectivity.
The biochemical modification of virions induced by
Nef that enhances infectivity is not known. Virions as-
sembled in the absence of Nef appear to contain wild-
type levels of viral RNA, reverse transcriptase activity,
and envelope glycoprotein (Env) (Aiken and Trono, 1995;
Chowers et al., 1995; Schwartz et al., 1995). Notably,
Nef-mediated enhancement of infectivity does not re-
quire specifically HIV-1 Env. Nef enhances the infectivity
of HIV-1 pseudotypes containing murine retroviral Env,
although the infectivity of pseudotypes containing vesic-
ular stomatitis virus G protein is relatively insensitive to
Nef (Aiken, 1997; Aiken and Trono, 1995; Miller et al.,
1995).
Recently, analysis of purified virions has revealed that
Nef is a virion–protein (Bukovsky et al., 1997; Pandori et
al., 1996; Welker et al., 1996). This observation suggests
the simple hypothesis that Nef acts to enhance infectivity
directly within the virion or after its delivery by the virion
to the newly infected target cell. The Nef protein within
virions is cleaved specifically by the viral protease, gen-
erating two fragments of ;7 kDa and ;20 kDa (Buk-
ovsky et al., 1997; Pandori et al., 1996; Welker et al., 1996).
Cleavage of recombinant NefHIV-NL43 protein by the HIV-1
protease in cell-free reactions occurs between amino
acid residues W57 and L58 (Freund et al., 1994b;
Gaedigk-Nitschko et al., 1995). These residues are cen-
tral to the sequence ACAWLEAQ, which is highly con-
served among HIV-1 isolates. With the exception of the
amino-terminal alanine that occurred as aspartate in
;50% of nef genes, these residues were 90–100% con-
served among uncultured HIV-1 nef alleles derived di-
rectly from infected individuals (Shugars et al., 1993).
Structural analysis of Nef protein using nuclear magnetic
resonance spectroscopy indicates that this cleavage site
is contained in a region just N terminal to a well-folded
“core” domain that contains the SH3-binding surface
(Freund et al., 1994a; Grzesiek et al., 1996a; Lee et al.,
1996). These structural features have led to the sugges-
tion that proteolytic cleavage in the virion would release
the well-folded core of Nef from the amino-terminal mem-
brane anchor, potentially freeing the Nef core for action
within the virion or within the target cell (Freund et al.,
1994a; Pandori et al., 1996).
In addition to their role as a target site for the HIV-1
protease, residues that compose the cleavage site (in
particular, W57 and L58) have been shown to participate
in an intramolecular interaction with a hydrophobic
pocket formed by two alpha helices in the well-folded
Nef core (Grzesiek et al., 1996a, 1996b; Lee et al., 1996).
Together, residues of the cleavage site and this pocket
form a hydrophobic patch on Nef protein that appears to
have a weak binding affinity for a peptide sequence
derived from the cytoplasmic tail of CD4 (Grzesiek et al.,
1996b). These structural and biochemical features have
suggested that these residues may be involved in a
direct binding interaction between CD4 and Nef. In sup-
port of such an interaction, certain cleavage site resi-
dues, specifically residues 57–59, have been shown to
be required for CD4 down-regulation, whereas dispens-
able for the localization of Nef to endocytic vesicles
(Greenberg et al., 1997). The relationship between these
observations, the intravirion proteolytic processing of
Nef, and enhancement of viral infectivity is unclear.
The inclusion of Nef protein and its proteolytic pro-
cessing within virions is of unknown biological rele-
vance. Indeed, a recent mutational analysis has sug-
gested that generation of the carboxyl-terminal core do-
main of Nef by intravirion proteolysis is insufficient for
enhancement of infectivity (Miller et al., 1997). To inves-
tigate further the relevance of these phenomena, a panel
of nef mutants characterized by a variety of intravirion
cleavage phenotypes has been generated. The infectiv-
ities of these mutant viruses have been measured after
production using a variety of cell types. The data indicate
that cleavage of Nef protein in virions does not correlate
directly with Nef-mediated enhancement of infectivity.
However, amino acid residues at the protease cleavage
site are critically important for enhancement of viral in-
fectivity. Interestingly, the importance of certain of these
amino acid residues for optimal infectivity is manifest
most dramatically when viruses are produced using T
cells (lymphoblastoid cell lines or primary lymphoblasts
derived from PBMCs) and not when viruses are pro-
duced using 293 or HeLa cells. The role of these amino
acids in CD4 down-regulation and the relationship be-
tween CD4 down-regulation and enhancement of infec-
tivity by this Nef domain are described.
RESULTS
Amino acid residues 54–60 in HIV-1 Nef govern the
specificity of intravirion proteolytic processing and
are necessary for optimal viral infectivity
To modulate cleavage of Nef protein within virions,
NL4–3-based proviral mutants containing altered amino
acid sequences at the putative cleavage site were con-
structed. Specificity of the HIV-1 protease is determined
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by contact with four amino acids on either side of the
scissile bond; the predicted octameric cleavage site of
NL4–3 Nef consists of amino acid residues 54–61, the
peptide sequence ACAWLEAQ (Freund et al., 1994b;
Gaedigk-Nitschko et al., 1995; Skalka, 1989). Using PCR-
based mutagenesis, mutant sequences encoding the nef
alleles were constructed (Table 1); these included three
alleles in which partially overlapping in-frame deletions
were engineered within the putative octameric cleavage
site and two alleles in which Nef peptide sequences
were replaced with sequences derived from a cleavage
site within Gag. These mutant alleles were cloned into
the pNL4–3 vector by exchanging the wild-type nef se-
quence between XhoI and PmlI with the XhoI–PmlI frag-
ments containing the desired mutations. The sequences
of all proviral mutants were confirmed by DNA sequenc-
ing. Proviral plasmids containing the mutated nef alleles
as well as the wild-type pNL4–3 and the nef-negative
pDS (Chowers et al., 1994), which encodes two prema-
ture termination codons (one at codon 9 and the other at
codon 21), were used to transfect 293 cells. After 72 h,
virus-containing supernatants were clarified of cellular
debris by centrifugation at 1000g followed by passage
through 0.45-mm nitrocellulose filters. Virions then were
purified by gel filtration chromatography using S-1000
Sephacryl columns as described previously (McKeating
et al., 1991; Pandori et al., 1996). For each virus, fractions
containing the peak concentrations of p24 antigen were
combined, and equal amounts of p24 antigen were con-
centrated by centrifugation at 23,500g before analysis by
immunoblot using a sheep, polyclonal, Nef-specific anti-
serum. As shown previously and in Fig. 1, virion-associ-
ated Nef protein was detected as both the 27-kDa full-
length and 20-kDa cleaved forms.
The immunoblot shown in Fig. 1 demonstrates the
variety of intravirion Nef cleavage patterns that charac-
terized these mutants. Importantly, virion preparations of
each mutant appeared to contain similar amounts of Nef
protein, indicating that these mutant gene products were
stably expressed to a degree such that membrane local-
ization and subsequent packaging of Nef protein into
virions could occur. These data indicated that residues
54–60 were critical for proteolytic processing of Nef
within virions. Deletion of five amino acids around the
putative scissile bond (D56–60, Fig. 1) and deletion of the
four amino acids constituting the amino half of the cleav-
age site (D54–57, Fig. 1) both blocked cleavage, whereas
in-frame deletion of the four amino acids constituting the
carboxyl half of the cleavage site (D58–61, Fig. 1) did not
affect cleavage substantially.
Two additional mutants were constructed and charac-
terized, each of which contained heterologous cleavage
sites in place of the native protease cleavage site within
Nef (Table 1). These mutants were designed to allow
cleavage of Nef using amino acid residues unrelated to
the native sequence. In the case of the mutant D56–
601Gag, this was accomplished by in-frame substitution
of the amino acid residues ATIMMQRG, which forms an
efficient proteolytic cleavage site in the Gag polyprotein
of HIV-1 between P2 and nucleocapsid, in place of the
native Nef sequence AWLEA (Erickson-Viitanen et al.,
1989). A mutant was also constructed that contained the
chimeric cleavage site ATIMLEAQ, which contains the
amino half of the P2/NC cleavage site and the carboxyl
half of the Nef cleavage site (D54–571ATIM). This con-
struct was designed to restore cleavage to the D54–57
mutant while potentially preserving with wild-type se-
quence the 20-kDa, carboxyl-terminal Nef fragment. Both
the D56–601Gag (Fig. 1) and the D54–571ATIM (Fig. 1)
viral mutants packaged and cleaved Nef with an effi-
ciency similar to, if not greater than, that of wild-type
virus. These data indicated that the proteolytic cleavage
site found in native HIV-1 Nef protein is exchangeable
FIG. 1. Immunoblot for Nef in wild-type and nef mutant virions. Virions
produced by transfected 293 cells were purified by filtration through
0.45-mm nitrocellulose filters followed by gel filtration chromatography
using S-1000 Sephacryl columns. The purified virions were concen-
trated by centrifugation, and 1 mg of p24 of each mutant was applied to
each lane of a 14% polyacrylamide gel. After transfer to a nitrocellulose
membrane, the blot was probed with a polyclonal sheep anti-Nef
antiserum followed by detection with peroxidase-conjugated donkey
anti-sheep secondary antibody and development with enhanced
chemiluminescent substrate. Nomenclature is as described in Table 1;
“Double-stop” contains two premature termination codons in the 59
terminus of the nef gene (Chowers et al., 1994).
TABLE 1
Amino Acid Sequences of Cleavage Site Mutants in NL4-3 Nef




D56–60 1 Gag -SNTNAACATIMMQRGQEEEEVGFP-
D54–57 1 ATIM -SNTNAATIMLEAQEEEEVGF-
a Indicates the cleavage site of recombinant Nef in vitro (Freund et
al., 1994b; Gaedigk-Nitschko et al., 1995).
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biochemically with a heterologous HIV protease cleav-
age site from the Gag protein. Mutant virions produced
from acutely infected CEM cells revealed cleavage phe-
notypes similar to those of the 293 cell-derived virions
shown in Fig. 1 (data not shown), indicating that cleav-
age of Nef protein within virions was not producer cell
specific.
To determine whether proteolytic processing of Nef
protein within virions correlated with enhancement of
infectivity, stocks of these mutant viruses were prepared
by transfection of CEM cells with proviral DNA and prop-
agation of the resulting virus to relatively high titer. Viral
stocks were also produced by allowing the cultures to
become chronically infected and then harvesting the
virions produced transiently during a 72-h interval. The
infectivities of these viral stocks were quantified using a
previously described infectious center assay, which uses
the CD4 positive HeLa cell line HT4–6C as the target
(Pandori et al., 1996). Exposure of monolayers of these
cells to virus stocks for 3 days results in the formation of
readily visible syncytia after fixation of the cells and
staining with crystal violet. These syncytia were counted,
and the amount of p24 antigen required for a syncytium-
forming unit was calculated for each viral stock. The
infectivity of each viral stock was then expressed relative
to the infectivity of wild-type virus.
Figure 2 shows the relative infectivities of each
mutant viral stock compared with the wild-type
(NL4–3) and nef-negative (DS or Dnef) controls. As
previously described, the infectivity of nef-negative
virus was only 10% that of wild-type virus. The infec-
tivities of the mutants containing deletions within the
cleavage site of Nef (D54–57, D56–60, and D58–61)
were indistinguishable from that of the nef-negative
virus and in no case exceeded 20% of wild-type levels.
The infectivities of mutants containing cleavage sites
derived from Gag (D54–571ATIM and D56–601Gag)
were also indistinguishable from that of nef-negative
virus. The relative infectivities of the mutants were
identical whether virions were produced during
spreading infection in cultures of transfected CEM
cells (Fig. 2A) or produced transiently from chronic
producer CEM cells (Fig. 2B); these data excluded the
possibility of a systematic artifact introduced by the
comparison of virions that had propagated at different
rates. The inability of the alleles D58–61,
D56–601Gag, and D56–601ATIM to enhance infectiv-
ity, despite their ability to generate Nef proteins that
were incorporated and cleaved in the virion to an
extent similar to that of the wild type, indicated that the
cleavage of Nef in virions was not sufficient for Nef-
mediated infectivity enhancement. Nevertheless, the
amino acid residues that constitute the proteolytic
cleavage site appeared to be essential for optimal
infectivity.
Amino acid residues at the cleavage site are
important for Nef-mediated CD4 down-regulation
The observations described above suggested that this
domain in Nef might perform a function in addition to
provision of a cleavage site that is important for en-
hancement of infectivity. Structural data have suggested
that several of the residues of the cleavage site partici-
pate in the formation of a hydrophobic surface on Nef
that appears to bind with weak affinity to a peptide
sequence corresponding to the cytoplasmic tail of CD4
(Grzesiek et al., 1996b). These structural data suggest
that a second function performed by this domain might
be related to CD4 down-regulation.
To determine the role of the cleavage site domain in
CD4 down-regulation, the mutant nef alleles D54–57,
D56–60, and D58–61 were cloned into the eukaryotic
expression vector pCIneo for testing in a 293 cell-based
assay. Each Nef expression vector was used together
with a CD4 expression vector and a vector that ex-
presses the green fluorescent protein (GFP) to transfect
293 cells. After 72 h, the cells were stained using the
monoclonal antibody Leu3a conjugated to phycoerythrin
and analyzed for surface expression of CD4 using flow
cytometry. Figure 3A shows the expression of CD4 on the
surface of cells transfected with the various mutant nef
alleles compared with cells transfected with wild-type
nef or the empty vector (non-nef-expressing) control. Un-
der the conditions of this assay, expression of wild-type
Nef reduced the percentage of CD4-positive cells by
;3-fold, from 72% to 25% of the GFP-positive population.
In contrast, the mutants D54–57, D56–60, and D58–61
had little or no detectable effect on CD4 expression.
Immunoblot analysis of the transfected cells used in
these flow cytometry experiments confirmed equivalent
expression of all Nef gene products (Fig. 3B). These data
indicated that residues of the proteolytic cleavage site
were important for CD4 down-regulation as well as for
optimal infectivity.
Interestingly, the electrophoretic mobility of the
D54–57 Nef protein appeared to be retarded relative to
wild-type Nef and the other deletion mutants. Similar
anomalous mobility was observed for an alanine substi-
tution mutant, W57A/L58A (data not shown). Such mobil-
ity shifts were not observed for the D58–61 or D56–60
mutants. Curiously, the anomalous mobility of D54–57
Nef was not observed in immunoblots of virions pro-
duced by 293 or CEM cells (Fig. 1; data not shown).
The infectivity phenotypes of the cleavage site
mutants depend on the producer cell type
To examine the possibility of a causal relationship
between the effect of the cleavage site domain on CD4
down-regulation and its effect on viral infectivity, the
infectivities of the cleavage site mutants were measured
after virion production by CD4-negative cells. Mutant
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viruses were prepared by transient transfection of 293
cells, a CD4-negative, adenovirus DNA-transformed hu-
man embryonic kidney cell line. The infectivities of the
virus stocks were measured using the syncytium forma-
tion assay described above (Fig. 4). The infectivity of the
nef-negative virus was 10% that of the wild type, similar
to the data obtained for the CEM-derived viruses shown
in Fig. 2. However, certain cleavage site mutants were
minimally if at all impaired after production using 293
cells. Specifically, the mutants D54–57 and
D54–571ATIM were nearly as infectious as the wild type
(80–70% of wild-type infectivity) when produced using
FIG. 2. Infectivity of nef-mutant viruses produced from CEM cells. (A) Viral stocks produced during spreading infection after transfection of CEM
cells with the indicated proviral clones. (B) Viral stocks produced by transient production from chronic producer CEM cells. Virus-containing
supernatants were quantified by p24 ELISA. The viral stocks were used to inoculate monolayers of HeLa-CD4 (HT4–6C) cells in a syncytium formation
assay, and the percent wild-type infectivity was calculated as described in the Materials and Methods. The values in A are the average of duplicate
assays of each viral stock; error bars are the standard deviation of the mean. The results are representative of three independently produced sets
of viral stocks. The values in B are the average of two independently produced sets of viral stocks, each titered twice; error bars are the standard
deviation of the mean. Nomenclature is as described in Table 1. “DS” contains two premature termination codons in the 59 terminus of the nef gene
(Chowers et al., 1994). “Dnef” contains a deletion in the 59 terminus of the nef gene, which introduces a frameshift (Spina et al., 1994).
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293 cells (Fig. 4); in contrast, these mutants were phe-
notypically nef defective (10% of wild-type infectivity)
when produced using CD4-positive, T lymphoblastoid
CEM cells (Fig. 2). The D58–61 mutant was characterized
by an intermediate phenotype when produced using 293
cells (50% of wild-type infectivity), in contrast to the nef-
defective phenotype observed when produced using
CEM cells. The mutant D56–60 was characterized by a
relatively defective infectivity phenotype whether 293 or
CEM cells were used as viral producers.
These data indicated that the viral determinants of
Nef-mediated infectivity enhancement varied in different
producer cell environments. The greatest variation was
revealed by the mutant D54–57; residues 54–57, although
FIG. 3. (A) CD4 down-regulation in transfected 293 cells. Cells were transfected with 1 mg of a GFP expression vector, 1 mg of a CD4 expression
vector (pCMX-CD4) and either pCIneo or a pCIneo-based nef expression vector (2 mg) as described in Materials and Methods. After 72 h, cells were
stained with anti-CD4 (Leu 3a) conjugated to PE and analyzed by two-color flow cytometry for GFP (the transfection marker) and PE (surface CD4).
The gates for GFP-positive and PE- (CD4)-positive cells were set as described in the Materials and Methods. The percentage shown in each analysis
is the percentage of GFP-positive cells that were also positive for PE (CD4). (B) Immunoblot of transfected 293 cells used in the CD4 down-regulation
assay. The transfected 293 cells (105) used in the CD4 down-regulation assay shown in Fig. 3A were assayed by immunoblot for Nef protein as
described in the Materials and Methods.
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required in CEM T cells, were essentially dispensable in
293 cells. Because D54–57 Nef failed to cleave in virions
(Fig. 1), these data indicated that when virions were
assembled in 293 cells, intravirion cleavage was unnec-
essary for Nef-mediated infectivity enhancement. Under
these producer cell conditions, deletion of residues
54–57 further appeared to define a novel class of nef
allele that is specifically defective in CD4 down-regula-
tion but able to enhance viral infectivity.
Given the cell type-specific infectivity defect of the
D54–57 mutant, we considered further the possibility that
CD4 down-regulation might be causally linked to at least
a fraction of the net effect of Nef on viral infectivity when
virions are produced from CD4-positive cells. First, we
performed experiments in which viruses were produced
from 293 cells that had been transfected with the proviral
plasmids either with or without cotransfection of a CD4
expression plasmid. Overexpression of CD4 in this set-
ting reduced the infectivities of both wild-type and nef-
negative viruses to unmeasurable levels (data not
shown). These results were qualitatively similar to pre-
vious studies indicating an inhibitory effect of CD4 over-
expression in the producer cell on viral infectivity (Mar-
shall et al., 1992). However, we considered these exper-
iments to be potentially problematic with respect to the
relevance of the levels of CD4 expression achieved;
artifacts resulting from supraphysiological levels of CD4
expression, for example Env shedding or sequestration
of Env in the endoplasmic reticulum, might account for
the observed inhibition of infectivity.
To provide a level of CD4 that was as relevant as
possible as the test variable, we identified producer cell
lines that were similar in origin but differed with respect
to the presence or absence of physiological levels of
CD4 expression. To identify these lines, the levels of CD4
expression on the surfaces of two CD4-positive HeLa
cell lines [HeLa-HT4–6C and HeLa-1022 (Chesebro et al.,
1991)] were compared using flow cytometry with those of
CEM cells and primary CD4-positive T lymphoblasts
(data not shown). The surface expression of CD4 on cells
of the HeLa-1022 line was quantitatively most similar to
that of CEM cells and primary lymphoblasts (Fig. 5). Cells
of this CD4-positive HeLa cell line were then compared
with CD4-negative HeLa cells as viral producers. By
comparison to the data obtained using CD4-negative
HeLa cells, CD4 expression on the surface of HeLa-1022
cells had no effect on the infectivity of wild-type virus but
increased modestly (2-fold) the infectivity of nef-negative
virus (Fig. 6). As was the case when produced using 293
cells, the infectivity of the D54–57 mutant was relatively
unimpaired when produced using CD4-negative HeLa
cells, retaining .70% of wild-type activity (Fig. 6). When
produced using the CD4-positive HeLa-1022 cells, the
D54–57 mutant similarly retained ;60% of wild-type in-
fectivity. Also in concordance with the data obtained
using 293 cells as producers, the D58–61 mutant re-
tained 70% of wild-type infectivity when produced using
CD4-negative HeLa cells. Like the D54–57 mutant, the
infectivities of D58–61 viruses produced by CD4-negative
HeLa and CD4-positive HeLa-1022 cells were not signif-
icantly different. Unexpectedly, but similar to the effects
observed for the nef-negative control, the infectivity of
FIG. 4. Infectivity of nef mutant viruses produced from 293 cells. Virus-containing supernatants were harvested from transfected 293 cells and
quantitated by p24 ELISA. The viral stocks were used to inoculate monolayers of HeLa-CD4 (HT4–6C) cells in a syncytium formation assay, and the
percent wild-type infectivity was calculated as described in the Materials and Methods. The values are the average infectivities of two independently
produced viral stocks, each titered twice; error bars are the standard deviations of the mean.
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the D56–60 mutant was 2-fold greater (67% of wild-type
infectivity) when produced from CD4-positive HeLa-1022
cells than when produced from CD4-negative HeLa cells
(34% of wild-type infectivity). Although these data sug-
gested that CD4 expression may modulate slightly the
phenotype of certain nef mutants, they also indicated
that CD4 expression alone was unlikely to account for
the cell type-specific contribution of cleavage site resi-
dues to Nef-mediated infectivity enhancement.
It remained possible, however, that CD4 played a sig-
nificant role in the virological function of the cleavage
site domain in cooperation with another T cell-specific
factor. To examine this possibility, viral stocks of the
mutants D54–57, D56–60, and D58–61 were prepared by
transfection and subsequent propagation of virus using
A2.01/CD4:LL-AA cells (Moutouh et al., 1998). This cell
line was obtained by transduction of the CD4-negative T
cell clone A2.01 with a retroviral vector containing a CD4
gene encoding alanine substitutions of leucine residues
413 and 414 in the CD4 cytoplasmic tail, followed by
selection of cells expressing high levels of CD4 from the
bulk population using flow cytometry (Moutouh et al.,
FIG. 5. Surface CD4 expression on CEM cells, HeLa-1022 cells, A2.01/CD4: LL-AA cells, and purified CD4-positive primary T cells. Cells (2 3 105)
of each type were stained with anti-CD4 (Leu3a) conjugated to phycoerythrin and analyzed by flow cytometry. The value shown in each histogram
is the mean peak fluorescence for PE staining. CD4-positive primary T cells were isolated from PBMC as described previously (Pandori et al., 1996).
The primary cells were stimulated with PHA (3 mg/ml) and interleukin-2 (5 U/ml) 2 days before analysis by flow cytometry.
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1998). The leucine residues 413 and 414 have been
reported as essential for binding of the cytoplasmic tail
of CD4 to Nef, and alanine substitution of these residues
renders the CD4 molecule refractory to Nef-mediated
CD4 down-regulation (Aiken et al., 1994; Grzesiek et al.,
1996b). The infectivities of the cleavage site mutants
FIG. 6. Infectivity of nef mutant viruses produced from either CD4-negative HeLa cells or CD4-positive HeLa-1022 cells. Virus-containing
supernatants were harvested from transfected cells and quantified by p24 ELISA. The viral stocks were used to inoculate monolayers of HeLa-CD4
(HT4–6C) cells in a syncytium formation assay, and the percent wild-type infectivity was calculated as described in the Materials and Methods. The
values are the averages of duplicates; error bars are the standard deviation of the mean. The results are representative of two independently
produced sets of viral stocks. The absolute infectivities for viruses produced from CD4 negative HeLa cells (in pg of p24 per syncytium-forming- unit)
were NL4–3, 1.0; DS, 11.2; D54–57, 1.4; D56–60, 2.8; and D58–61, 1.4. The absolute infectivities for viruses produced from CD4-positive HeLa cells (in
pg of p24 per syncytium-forming unit) were NL4–3, 1.0; DS, 5.1; D54–57, 1.8; D56–60, 1.5; D58–61, 1.5.
FIG. 7. Infectivity of nef mutant viruses produced using A2.01/CD4:LL-AA cells, which express a mutant CD4 molecule (LL-413, 414-AA mutation of
the cytoplasmic tail). Virus-containing supernatants were harvested from transfected cells and quantified by p24 ELISA. The viral stocks were used
to inoculate monolayers of HeLa-CD4 (HT4–6C) cells in a syncytium formation assay, and the percent wild-type infectivity was calculated as described
in the Materials and Methods. The values are the average of duplicate assays of each viral stock; error bars are the standard deviation of the mean.
The results are representative of two independently produced sets of viral stocks.
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produced using these cells are shown in Fig. 7. As has
been the case for all producer cells studied, the infec-
tivity of nef-negative virus was markedly less than that of
the wild type (15% of wild-type infectivity). Similar to the
results obtained using CEM cells as viral producers, and
unlike the results obtained using 293 and HeLa cells, all
three cleavage site mutants (D54–57, D56–60, and D58–
61) were markedly impaired in infectivity when produced
using A2.01/CD4:LL-AA cells. However, the magnitude of
the defects of these mutants when produced from A2.01/
CD4:LL-AA cells was slightly less than when produced
from CEM cells. This observation suggested that CD4
down-regulation might contribute a small fraction of the
net nef phenotype when virions are produced from CD4-
positive T cells. Nevertheless, these data indicated that
the cleavage site residues remained critical for infectivity
enhancement in the T cell environment even when the
potential for an interaction between Nef and CD4 has
been eliminated and CD4 down-regulation by Nef was
predicted not to occur. Together, the data of Figs. 6 and
7 argue against a hypothesis in which cleavage site
residues are important for infectivity solely because they
are required for CD4 down-regulation.
Cleavage site residues are essential for infectivity
enhancement when virions are assembled in primary
lymphoblasts
The above data indicated that residues of the cleavage
site performed a function essential to infectivity en-
hancement when virions were produced using continu-
ous T cell lines. To establish the relevance of these
observations, the infectivities of the cleavage site mu-
tants were evaluated after production using primary PB-
MCs. High-titer viral stocks produced from CEM cells
were used to infect PBMCs that were stimulated with
PHA and interleukin-2. Twelve days after the initiation of
infection, virus-containing supernatants were harvested,
and viral infectivities were measured using the syncy-
tium formation assay described above (Fig. 8A). In con-
cordance with the data obtained using CEM and A2.01 T
cells as viral producers, the infectivities of the cleavage
site mutants were indistinguishable from that of nef-
negative virus. These data underscore the importance
and relevance of this domain with respect to Nef-medi-
ated infectivity enhancement. They also support the gen-
eralization that the molecular action of this domain is
most critical within the T cell environment.
To establish further the relevance of this domain, the
rates of propagation of the cleavage site mutants were
determined in primary lymphoblasts (Fig. 8B). The mu-
tants D56–60 and D58–61 were intermediate in growth
rate, whereas the mutant D54–57 was characterized by a
growth rate that was almost as attenuated as that of
nef-negative virus. These data indicated that the virolog-
ical importance of this domain was not limited to the
context of HeLa-CD4 cells as the targets for infection.
DISCUSSION
The protease cleavage site in HIV-1 Nef appears to be
a focal point within the protein for a variety of biochem-
ical, structural, and functional effects. First identified us-
ing cell-free reactions between recombinant proteins,
the cleavage site acquired biological relevance with the
observation that Nef protein is incorporated into the
virion and is processed there by the viral protease
(Freund et al., 1994b; Gaedigk-Nitschko et al., 1995; Pan-
dori et al., 1996; Welker et al., 1996). These findings
suggested a role for virion incorporation and proteolytic
cleavage in Nef-mediated enhancement of virion infec-
tivity. Structural data have indicated that the cleavage
site is located between a relatively unstructured amino-
terminal region and a relatively well-folded, globular core
region in Nef that contains potential protein-interaction
domains such as an SH3-binding surface (Grzesiek et
al.,1996a; Lee et al., 1996). In addition, residues of the
cleavage site, in particular W57 and L58, participate in an
intramolecular interaction with residues of a hydrophobic
pocket formed by two alpha helices of the core (Grzesiek
et al., 1996a). Together, residues of the cleavage site and
this pocket form a hydrophobic surface with a weak
binding affinity for a peptide sequence within the cyto-
plasmic tail of CD4 (Grzesiek et al., 1996b). These find-
ings have suggested a direct role for these residues in
Nef-mediated CD4 down-regulation. Here, we have
sought to define the relationships between these bio-
chemical and structural features and the functional prop-
erties of Nef with respect to CD4 down-regulation and
infectivity enhancement. In summary, residues 54–61 are
the primary target within Nef for the viral protease during
virion maturation, are essential for CD4 down-regulation,
and are critical for enhancement of infectivity in a con-
ditional fashion that depends on the producer cell envi-
ronment.
When virions are assembled in T cells, residues of the
cleavage site are essential for optimal infectivity; cleav-
age itself, however, is insufficient for the virological effect
of this domain. Mutational analysis of residues 54–61 of
HIV-1 Nef confirmed that the cleavage site used within
virions is closely related if not identical to that observed
using recombinant proteins. The infectivities of viruses
that contain cleavage-resistant Nef proteins (D54–57 and
D56–60) were equivalent to that of nef-defective viruses.
However, mutants of this region for which virion-associ-
ated Nef was cleaved efficiently were nevertheless de-
fective for enhancement of infectivity. These included a
mutant in which the carboxyl half of the cleavage site
was deleted (D58–61) and two mutants in which residues
essential for cleavage were replaced with residues of
the Gag P2/NC cleavage site. These data did not support
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a model in which infectivity enhancement requires pro-
teolytic release of the well-folded Nef core for function
within the virion or the target cell. Instead, these data
indicated that these residues perform a function in ad-
dition to provision of a cleavage site that is required for
optimal infectivity.
Certain cleavage site residues, in particular, residues
54–57, were most important to infectivity during virion
assembly in CEM cells, A2.01 cells, and primary lympho-
blasts and were less important during virion assembly in
293 cells and HeLa cells; these observations suggested
that the hypothetical second function of this region might
involve a T cell-specific molecule or process. In initial
support of this hypothesis, residues of the cleavage site
were found to be required for Nef-mediated CD4 down-
regulation. This observation suggested that a Nef–CD4
interaction or CD4 down-regulation itself might be cen-
tral to the mechanism by which this domain contributes
FIG. 8. (A) Infectivity of nef mutant viruses produced from primary PBMCs. Viral stocks produced by PBMCs as described in Materials and Methods
were used to inoculate monolayers of HeLa-CD4 (HT4–6C) cells in a syncytium formation assay, and the percent wild-type infectivity was calculated.
The values were derived from a single titration of viral stocks. (B) Growth rates of nef-mutant viruses in PBMCs. Cells (2 3 106) were stimulated with
PHA (3 mg/ml) and interleukin-2 (20 U/ml) 3 days before inoculation with viral stocks derived from transfected CEM cells (200 ng of p24 antigen). The
inoculated cells were washed and incubated at 37°C, and the concentrations of p24 antigen in the culture supernatants were determined by ELISA.
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to infectivity. In one such scenario, down-regulation of
CD4 would be an essential component of infectivity en-
hancement when virions are produced from CD4-positive
cells but would be dispensable when virions are pro-
duced from CD4-negative cells. However, comparison of
virions assembled in different producer cells suggested
that CD4 down-regulation is unlikely to be the sole func-
tion of this domain. The expression of CD4 on HeLa cells
in amounts comparable to that of CEM cells and primary
T lymphoblasts did not create a producer cell environ-
ment in which residues 54–57 acquired a greater role in
enhancement of infectivity. Furthermore, these residues
were important for optimal infectivity, even during virion
assembly in T cells (A2.01/CD4:LL-AA) that expressed a
CD4 molecule that cannot be down-regulated by Nef.
Taken together, these data indicated that the impor-
tance of residues at the protease cleavage site for the
virological function of Nef is independent of both intra-
virion Nef processing and cell surface CD4 down-regu-
lation. What, then, might be the function of this domain?
Notably, the characteristics of each of the three in-frame
deletion mutants analyzed were unique. This observation
suggests that mutations in different regions of the cleav-
age site affect differentially an unidentified parameter
that influences the function of Nef. One possibility is that
the hydrophobic surface in which certain cleavage site
residues (W57 and L58) reside interacts with a cellular
factor (in addition to CD4) through which Nef operates to
enhance infectivity. A second possibility is that these
mutations affect the formation of an intramolecular fold in
Nef between residues W57 of the cleavage site and L97
of the Nef core (Grzesiek et al., 1996b). Potentially, the
dissimilar electrophoretic mobilities of these mutants
may provide evidence for differental effects on this ter-
tiary fold.
The explanation for the influence of the producer cell
type on the infectivity phenotypes of these mutants re-
mains elusive. It is interesting to note that differences in
the infectivity phenotypes observed for cleavage site
mutants of HIV-1 Nef after production by 293 and CEM
cells have been described recently (Chen et al., 1998). In
particular, alanine substitution of residues 57 and 58
yielded a noncleavable Nef protein, and virus encoding
this mutation retained significant infectivity when pro-
duced from 293 cells despite a marked defect in infec-
tivity when produced from CEM cells (Chen et al., 1998).
This characterization is similar to that of the D54–57
mutant described herein. As mentioned above, one pos-
sibility for the cell type specificity of these mutants is that
enhancement of infectivity requires an interaction be-
tween certain cleavage site residues and a cellular fac-
tor found specifically within T cells. A second possibility
is that Nef performs more than one function, each of
which contributes to infectivity; these functions would
have different genetic determinants as well as different
relative importances in various producer cells. A third
possibility is that mutations at the cleavage site may
disrupt the tertiary structure of Nef. Such a folding dis-
turbance would be predicted to affect CD4 down-regu-
lation due to the involvement of the intramolecular inter-
action between cleavage site residues and the Nef core
in the formation of a CD4 binding surface. However, such
a folding disturbance could also affect Nef-mediated
infectivity enhancement, even if the cleavage site resi-
dues were not involved directly in the molecular interac-
tion by which Nef enhances infectivity. If such misfolding
caused only a partial loss of Nef function, then this loss
might be manifest more profoundly in certain cell types
due to different levels of Nef expression by the provirus.
Despite these uncertainties, the use of different pro-
ducer cells allowed the observation of a novel genetic
separation of CD4 down-regulation from enhancement of
infectivity. When viruses were produced from 293 cells,
the mutant D54–57 defined a region of Nef that is re-
quired for CD4 down-regulation but is not required for
infectivity enhancement; such a Nef mutant has not been
described previously. Interestingly, a mutant of the SH3-
binding surface of Nef has been characterized previously
by directly opposite phenotypes; this mutant is reportedly
deficient in infectivity while wild type with respect to CD4
down-regulation (Goldsmith et al., 1995; Wiskerchen and
Cheng-Mayer, 1996).
These observations also suggest the need for caution
with respect to the choice of the producer cell used for
the analysis of nef mutants. For example, exclusive use
of 293 cells as producers would have failed to charac-
terize the D54–57 mutant as defective, despite its
marked attenuation in cultures of primary lymphoblasts.
Although the characterization of the D54–57 mutant us-
ing 293 cells indicated that the amino-terminal half of the
cleavage site, the ability to down-regulate CD4, and the
intravirion cleavage of Nef are all largely dispensable for
infectivity enhancement under certain conditions of viral
assembly, these observations diminish neither the criti-
cal importance of this domain for Nef function during
viral assembly in T cells nor its importance for optimal
replication of HIV-1 in primary T lymphoblasts.
MATERIALS AND METHODS
Plasmid construction
For construction of proviral mutants, PCR mutagenesis
was performed to create in-frame deletions or amino
acid substitutions in the nef reading frame. PCR products
and the proviral vector pNL4–3 were cut with XhoI and
PmlI. The cut PCR products were ligated into the pNL4–3
backbone using T4 DNA ligase (Boehringer-Mannheim)
and the ligation products were used to transform Esch-
erichia coli. Minipreparations of plasmid DNA from trans-
formants were analyzed by nucleotide sequencing using
nef-specific primers, PRISM Ready Reaction DyeDeoxy
Terminator Cycle Sequencing Kit, and an ABI 373A Au-
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tomated Sequencer. For construction of subgenomic nef
expression vectors, mutant nef genes created by PCR
mutagenesis were engineered to contain SalI and EcoRI
ends. The PCR products and the eukaryotic expression
vector pCineo (Promega) were cut with SalI and EcoRI.
The PCR products were ligated into the pCineo vector
using T4 DNA ligase followed by transformation of Esch-
erichia coli with the ligation products. Transformants
were screened for the presence of inserts by restriction
enzyme digestion with XhoI and Pml I. Candidate vectors
were sequenced as described above.
Cell lines
CEM cells were maintained in RPMI 1640 culture me-
dium supplemented with 10% FBS, 2 mM glutamine, and
penicillin–streptomycin. The 293 cells were maintained
in EMEM supplemented with 10% FBS, 2 mM glutamine,
and penicillin–streptomycin. HeLa cells were maintained
in DMEM, which was also supplemented as above.
A2.01 CD4:(LL-AA) cells were derived by transduction of
CD4-negative A2.01 cells with a retroviral vector encod-
ing a human CD4 gene in which the leucine residues at
positions 413 and 414 were replaced with alanines; the
cells were selected for relatively high levels of cell sur-
face CD4 expression using flow cytometry and were
maintained in supplemented RPMI 1640 medium as de-
scribed with the addition of G418 to a concentration of
500 mg/ml (Moutouh et al., 1998). HeLa-1022 cells and
HeLa HT4–6C cells were maintained as described for
the parental HeLa cells with the addition of 500 mg/ml
G418 (Chesebro et al., 1991). Primary cultures of PBMCs
were maintained in RPMI 1640 supplemented with 10%
FBS, 2 mM glutamine, and penicillin–streptomycin. Pri-
mary cells were stimulated with PHA (to a final concen-
tration of 3 mg/ml) and interleukin-2 (to a final concen-
tration of 20 U/ml) 3 days before infection.
Production of viral stocks
To produce virus from CEM cells, proviral plasmid
DNA (1 mg) of each virus was combined with 5 mg of
Lipofectin (GIBCO BRL) and incubated at 37°C with 106
CEM cells in 1 ml of Optimem (GIBCO BRL) for 5 h.
Transfected cells were then diluted with 3 ml of supple-
mented RPMI medium. Cultures were split 1:3 every 3–4
days. After 9 days, when the cytopathic effect was ex-
tensive, the cultures were centrifuged at 1000g to pellet
the cells, and the virus-containing supernatant was
passed through a 0.45-mm filter. Aliquots of filtered su-
pernatant were frozen at 280°C. In addition, the trans-
fected cultures of CEM cells were maintained for an
additional 2–3 weeks to allow the outgrowth of chronic
producer cells. These cells were washed, resuspended
in fresh media, and incubated for 72 h before the collec-
tion and storage of virus-containing supernatants as de-
scribed above.
To produce virus from 293 cells, 106 cells were plated
in each 35-mm well of a six-well plate 24 h before
transfection. Transfection was performed by the calcium
phosphate method using the Cell-Phect transfection kit
(Pharmacia) as specified by the manufacturer and with 3
mg of proviral vector. After 72 h, virus-containing super-
natants were pooled, and cellular debris was removed
by centrifugation at 1000g for 10 min. Supernatants were
then passed through a 0.45-mm filter, and aliquots were
frozen at 280°C.
To produce virus from HeLa or HeLa-1022 cells, 5 3
105 cells were plated in each 35-mm well of a six-well
plate 24 h before transfection. Transfection was per-
formed using Lipofectamine (GIBCO BRL). Briefly, 1 mg of
proviral DNA was combined with 12 mg of Lipofectamine
in 500 ml of Optimem medium, and the mixtures were laid
over plated cells and incubated at 37°C for 5 h. After
incubation, 1.5 ml of supplemented DMEM was added to
the cells. After 72 h, virus-containing supernatants were
pooled and centrifuged at 1000g for 10 min and aliquots
were frozen at 280° C.
To produce virus from primary PBMC, cells (2.5 3 106)
were stimulated with PHA (3 mg/ml) and interleukin-2 (20
U/ml) before incubation for 6 h at 37°C with 2 ml of viral
stocks prepared by transfection of CEM cells (1 3 106 pg
of p24/ml). After incubation, cells were washed three
times with supplemented RPMI 1640 followed by resus-
pension of cells in 3 ml of medium supplemented with
interleukin-2 (to a final concentration of 20 U/ml). Fresh,
PHA- and interleukin-2-stimulated PBMCs (2 3 106) were
added to the cultures every 4 days. After 12 days, in-
fected cultures were centrifuged at 1000g for 10 min to
remove cellular debris. Virus-containing supernatants
were aliquoted and frozen at 280°C.
Purification of virions
For the analysis of virion-associated Nef protein, HIV-1
virions were purified essentially as described previously
(Pandori et al., 1996). Supernatants from cultures of 293
cells transfected with a proviral vector (pNL4–3 or a
mutant vector) were pooled 72 h after transfection. Virus-
containing supernatants (12 ml containing ;1.2 3 107 pg
of p24) were centrifuged at 800g, and the resulting su-
pernatants were passed through 0.45-mm filters. The
filtrates were concentrated by centrifugation at 23,500g
for 1 h at 4°C. The virion pellets were resuspended in
100 ml of supplemented RPMI 1640 medium. The con-
centrated virion solutions were loaded onto 2.5-ml gel
filtration columns containing Sephacryl S-1000 (Pharma-
cia). PBS (2 ml) was added to the column, and the eluate
was collected in 100-ml fractions. Fractions were ana-
lyzed by ELISA for their content of p24. Peak fractions
were pooled, quantified by p24 ELISA, centrifuged at
23,500g for 1 h at 4°C, and resuspended in 10 ml of
Western loading buffer [63 mM Tris–HCl, pH 6.8, 12.5%
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(vol/vol) glycerol, 2% (wt/vol) SDS, 5% (vol/vol) b-mercap-
toethanol, and 0.003% (wt/vol) bromophenol blue].
Infectivity assay
The infectivities of virus stocks were determined using
a CD4-expressing HeLa cell line (HT4–6C) in a syncytium
formation assay as described previously (Pandori et al.,
1996). Briefly, 5-fold dilutions of each virus stock in
DMEM supplemented with 4% FBS, 2 mM glutamine, 0.5
mg/ml Polybrene, and 8 mg/ml DEAE–dextran were
placed on a monolayer of HT4–6C cells in microtiter
wells. Three days later, the wells were fixed in methanol
and stained with crystal violet, and the syncytia were
counted. Absolute infectivities of each viral stock were
calculated by determining the number of syncytium-form-
ing units per picogram of p24 of virus. The percent
wild-type infectivity of each mutant was calculated by
dividing the infectivity of the mutant by the infectivity of
the wild-type virus and multiplying by 100.
CD4 down-regulation assay
For determination of CD4 down-regulation by mutant
nef alleles, 293 cells were cotransfected with phGFP-
S65T (Clontech) (1 mg), pCMX-CD4 (1 mg) (Aiken et al.,
1994), and either pCineo (2 mg) or a pCineo vector engi-
neered to express either wild-type nef or a mutant nef
gene (2 mg) by the calcium phosphate method. To set the
gate for GFP-positive cells, cells transfected with pCMX-
CD4 only were used. To set the gate for CD4-positive
cells, cells transfected with phGFP-S65T only were used.
After 72 h, transfected cells (;2 3 106) were harvested
and centrifuged at 800g for 5 min. Cells were resus-
pended in 200 ml of PBS (pH 7.4), 2% FBS, and 0.1%
sodium azide. Then, 100 ml of cells were saved for
Western blot analysis. To the remaining 100 ml of cells, 10
ml of Leu3a anti-CD4 (Becton-Dickenson) conjugated to
phycoerythrin (PE) was added, and the cells were
stained for 30 min at 4°C. Cells then were washed twice
in 2 ml of PBS supplemented as described above.
Washed cells were resuspended in 500 ml of PBS without
FBS, and 500 ml of 2% paraformaldehyde was added as
a fixative. Fixed cells were analyzed for GFP expression
and PE staining by two-color flow cytometry.
Immunoblot assays
Immunodetection of Nef protein was performed es-
sentially as described previously (Pandori et al., 1996).
Samples were resolved in a 4% stacking, 15% resolving
polyacrylamide minigel with the Laemmli discontinuous
buffer system and electroblotted onto 0.2-mm pore size
nitrocellulose membranes. The membranes were incu-
bated in Super-Block blocking buffer (Pierce) for 45 min
at room temperature. They were then incubated over-
night at 16°C in blocking buffer plus a 1:2000 dilution of
a polyclonal sheep antiserum raised to recombinant
NL4–3 Nef produced by Escherichia coli. Membranes
were washed twice for 10 min and once for 20 min in PBS
plus 0.1% (vol/vol) Tween 20. After washing, membranes
were incubated for 1 h in blocking buffer plus 1:100,000
donkey anti-sheep antibody conjugated to peroxidase
(binding site). Immunoreactive product was detected by
enhanced chemiluminescence with the ECL Western
blotting detection system (Amersham International). Ex-
posure times varied from 45 s to 3 min.
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